Skip to main content

Security report for ucb-biopharma.com.br

UCB Biopharma Ltda. · Healthcare · Brazil

Medium risk. 5 critical or high findings in Security headers, GDPR outside view and 1 other check.

Security score

70/100

Risk levelMedium

0–100, higher is better. How it is calculated

UCB Biopharma Ltda. is a regional branch of the global biopharmaceutical company UCB S.A., Belgium, specializing in innovative medicines for immunology and neurology. The website serves patients, healthcare professionals, and partners in Brazil, offering detailed information about therapeutic areas, patient support programs, and pharmacovigilance. The company positions itself as a trusted healthcare provider with a strong focus on improving patient quality of life through science-driven solutions. Technically, the website is built on Drupal CMS, hosted on Microsoft Azure infrastructure, and integrates modern analytics and cookie consent tools, reflecting a mature digital presence. Security posture is solid with HTTPS enforced and cookie consent mechanisms in place, though explicit security headers could be improved. Privacy compliance is well addressed with comprehensive privacy and cookie policies in Portuguese, aligned with GDPR principles. Overall, the site demonstrates good professionalism, trustworthiness, and user experience, supporting UCB's market position as a leading specialty pharma company in Brazil.

Scanned

NIS2 and GDPR posture

GDPR outside view
65/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

5 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Privacy Policy found

      GDPR requires a clear and accessible privacy policy

      What to do: Add a comprehensive privacy policy page and link to it prominently

    • High

      Third-party services without privacy policy

      Detected services: Google Analytics, Facebook, Twitter, LinkedIn, YouTube

      What to do: Document all third-party data sharing in your privacy policy

  3. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1
    • High

      SSL Certificate Expires Soon

      SSL certificate expires in 16 days

      What to do: Renew SSL certificate before expiration

      • NIS2 21(2)(h)
      • IR 2024/2690 9.2(c): Implementing Regulation (EU) 2024/2690, Annex point 9.2(c): Cryptography
      • NIST SC-17: NIST SP 800-53 Rev. 5 SC-17: Public Key Infrastructure Certificates

Need hands-on remediation? Email guard@offseq.com

Keep watching ucb-biopharma.com.br

This scan found 22 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
52
Security headers
65
Email security
75
DNS health
65
Network security
100
GDPR outside view
65
Average
70

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Breach exposure

Leaked credentials and lookalike domains from OffSeq Breach. The counts are free; the detailed lists are paid add-ons.

Dark web exposure

Add-on

Leaked records that mention ucb-biopharma.com.br, from OffSeq Breach.

No leaked records found

Breach holds no records for ucb-biopharma.com.br right now. New leaks arrive continuously, so monitoring on Breach alerts you if that changes.

Monitor on Breach (opens in a new tab)

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

The company operates in the healthcare sector focusing on specialty pharmaceuticals in immunology and neurology. Its business model includes research, development, and commercialization of innovative medicines, supported by patient assistance programs to enhance treatment adherence and outcomes. The website reflects a large enterprise with global parentage and local market adaptation. The presence of multiple country-specific domains and patient support initiatives indicates a broad partnership ecosystem and strategic market penetration. The company leverages digital channels and social media to engage stakeholders and maintain brand visibility. No direct revenue streams or financial data are disclosed on the site, but the comprehensive content and support programs suggest a customer-centric approach and investment in patient care.

Security posture

The website demonstrates a good security maturity level with HTTPS enabled and a cookie consent mechanism powered by OneTrust, ensuring user privacy and compliance. No exposed sensitive data or vulnerable libraries were detected in the HTML content. However, explicit security headers such as X-Frame-Options and X-Content-Type-Options are not clearly present and should be verified. There is no public security policy or incident response contact information, which could be improved to enhance transparency and readiness. The use of reputable third-party analytics and consent tools indicates a controlled data collection environment. Overall, the security posture is solid but could benefit from enhanced header configurations and published security policies.

Recommendations

  1. Implement and verify standard security headers (X-Frame-Options, X-Content-Type-Options) to mitigate clickjacking and MIME sniffing risks.
  2. Publish a clear security policy and incident response contact information to improve transparency and trust.
  3. Establish a public vulnerability disclosure program or security.txt file to encourage responsible reporting.
  4. Regularly audit third-party scripts and analytics tools for security and privacy compliance.
  5. Enhance SEO by adding a visible terms of service page and improving metadata completeness.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
UCB Biopharma Ltda.
Description
UCB Biopharma Brasil offers innovative medicines in immunology and neurology, aiming to improve quality of life for patients with serious diseases worldwide.
Key services
Immunology treatments, Neurology treatments, Patient support programs, Pharmacovigilance
Content quality
good
Branding
consistent

Technology

Stack
Drupal CMS, JavaScript, OneTrust cookie consent, Google Tag Manager, Siteimprove Analytics
Frameworks
Drupal
Performance
moderate
Mobile
good
Accessibility
good
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent mechanism implemented
  • No exposed sensitive data in HTML
  • Use of security-focused scripts

Analytics and tracking

Services
Siteimprove Analytics, Google Tag Manager
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Siteimprove Analytics
Marketing tools
OneTrust Cookie Consent
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenge.
  2. Content is professional and focused on healthcare and patient support.
  3. Strong privacy and cookie consent mechanisms implemented.
  4. Multiple social media channels linked for corporate presence.
  5. No visible security vulnerabilities or exposed sensitive data.
  6. WHOIS data supports legitimacy and consistency of domain ownership.
  7. No terms of service page explicitly found.
  8. No public security policy or incident response information found.
  9. Drupal CMS with modern scripts and analytics tools used.
  10. Good mobile optimization and accessibility features present.
Technical notes

Notes

The website is built on Drupal CMS, leveraging modern JavaScript libraries and hosted on Microsoft Azure DNS infrastructure, indicating a robust and scalable platform. Performance is moderate with asynchronous loading of analytics and consent scripts. The site is mobile optimized with responsive design and accessibility features such as skip links and ARIA roles. SEO is supported by canonical links and meta viewport tags. Cookie consent is managed via OneTrust, ensuring compliance with privacy regulations. The technical stack is modern and well integrated, though some security headers are not explicitly found in the HTML source and should be confirmed at the server level. Overall, the technical implementation supports a professional and user-friendly experience with room for minor security enhancements.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with ucb-biopharma.com.br. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review ucb-biopharma.com.br.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.